🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to scientists.

An International Challenge

Cases of gonorrhoea are on the rise globally, with figures suggesting more than 82 million instances per year. Particularly high rates are reported in Africa and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an important and timely development in the context of rising global incidence, the spread of superbugs and the very limited available drugs at this time.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has listed it as a "priority pathogen". Ongoing monitoring revealed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the American regulatory agency in December for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers anticipate that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, originating from the drugmaker GSK, gained clearance in concurrent days. This medication, which is additionally indicated for UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization GARDP partnered with the drug firm Innoviva to see it through.

“This approval represents a significant shift in the management of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Clinical Trial Data and Worldwide Availability

According to data released by a prominent scientific publication, the new drug successfully treated over nine in ten of cases of the STI. This places it at an similar efficacy with the typical regimen, which involves two antibiotics. The research enrolled over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the authority to license and sell the drug in many low-income and middle-income countries.

Medical professionals directly involved have voiced hope. Having a one-pill regimen like this is seen as a "critical tool" for public health efforts. This is viewed as crucial to lessen the impact of the infection for patients and to prevent the spread of extremely resistant gonorrhoea globally.